Osteoporosis: Relevance of Biomolecules for Diagnosis and Treatment

2025

Closed access Metadata (CSL-JSON)
DOI 10.2174/0109298673358991250210111956
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Osteoporosis, a metabolic disorder distinguished by decreased bone density and degradation of bone tissue microarchitecture, is a silent disease that evolves without any clinical symptoms or signs. An individual may not be aware of osteoporosis until a fracture occurs. The lifetime risk of osteoporosis is estimated to be between 10 and 20%. The disease can have intrinsic causes, such as genetic predisposition, aging, and lack of sex hormones. However, it can also occur secondary to calcium and vitamin D deficiencies due to the influence of various factors. With a global increase in osteoporotic fractures, there is a need for macro-level and micro-level interventions to prevent and treat osteoporosis and its complications. This review highlights the crucial role of various biomolecules in diagnosing and managing osteoporosis and emphasizes the importance of further research in the field.